A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice...

Area of Science:

• Vaccinology
• Parasitology
• Immunology

Background:

• An ideal malaria vaccine requires targeting multiple parasite stages and inducing both antiparasite and antidisease immunity.
• Previous research highlighted the importance of CD8(+) T cells in protection against malaria, a response effectively generated by viral vector platforms.
• Human adenovirus serotype 5 (Ad5) has a good safety profile for malaria vaccine trials but faces challenges due to pre-existing neutralizing antibodies.

Purpose of the Study:

• To develop a malaria vaccine candidate that elicits CD8(+) T cell responses and overcomes pre-existing anti-Ad5 immunity.
• To evaluate the efficacy of a chimeric Ad5/3 vector, engineered to resist pre-existing neutralizing antibodies.
• To assess the impact of vector dose on immune memory and protective efficacy.

Main Methods:

• Development of a chimeric Ad5/3 vector by replacing the Ad5 knob region with that of Ad3.
• Implementation of heterologous immunization regimens involving recombinant Ad vectors and protein.
• Assessment of protective efficacy and immune responses induced by Ad5/3 and Ad5 vectors.
• Evaluation of the effect of Ad vector dose on immune memory and protection.

Main Results:

• The chimeric Ad5/3 vector demonstrated protective efficacy comparable to the Ad5 vector.
• The Ad5/3 vector showed partial resistance to pre-existing anti-Ad5 neutralizing antibodies.
• Immunization dose significantly influenced the memory profile and protective efficacy of the Ad vectors.

Conclusions:

• The Ad5/3 vector represents a promising platform for malaria vaccine development, effectively inducing protective immunity while mitigating pre-existing anti-vector immunity.
• Further investigation into Ad5/3-based malaria vaccines is warranted.
• Optimizing vector dose is crucial for maximizing vaccine efficacy and durable immune memory.